Apparently a week is also a long time in biotech land. I was surprised with the change in emphasis between out licensing and co development to fund Phase 2. Who else might have been surprised? That might be existing partners with whom AdAlta had been progressing conversations in the latter stage of negotiations. When we get to the second of the interviews during last week during the Gems Investment Conference, the co development strategic option looks to be in the box seat.
We are told that BIO24 highlighted the pool of venture capital looking for a home.
One interesting point to note is that the co development option for AdSolis (AD-214) is in fact a version of the co development model that AdCella is offering Asian biotech in the cellular immunotherapy space. Perhaps what is good for the goose is also good for the gander.
1AD Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held
